Background: Combined recombinant human erythropoietin (rHuEPO) and iron therapy significantly reduced postoperative blood loss (PBL) and allogeneic blood transfusion (ABT) in elderly hip fracture (HF) patients. However, the minimum effective rHuEPO dosage and route had not been studied before. Objective: To evaluate the efficacy of single low dose preoperative intravenous rHuEPO on PBL and ABT in elderly HF. Methods: A randomized controlled trial (RCT) in 32 elderly HF underwent surgical intervention was conducted. The patients were randomly assigned to receive a single dose of 10 000 IU rHuEPO (EPO group, n = 16) or placebo (control group, n = 16) on admission. All patients were given 200-mg iron sucrose intravenously for 3 days after admission. Perioperative data, outcome related to PBL, ABT, rHuEPO adverse effects, and functional outcome during 1-year period were collected and analyzed. Results: There was no significant difference in demographic data, postoperative complication, and functional outcome between both groups (P < .05). Total hemoglobin loss (THL) and the number of patients receiving ABT in EPO group (2.1 ± 1.0 g/dL and 12 patients) did not significant differ from those in control group (2.2 ± 0.8 g/dL and 10 patients) (P = .81 and P = .44, respectively). However, EPO group demonstrated a nonsignificant greater in hemoglobin recovery (P = .07) and increase in reticulocyte count (P = .10). Conclusions: Combined single low dose preoperative intravenous rHuEPO with iron therapy does not significantly reduce PBL and ABT in elderly HF compared to who received intravenous iron therapy alone. However, this adjunct rHuEPO may hasten the hemoglobin recovery and helpful for the patients' outcome.
Introduction
Perioperative anemia is one of the most common problems in elderly hip fractures (HF) 1 due to their preexisting comorbidities and a large amount of perioperative blood loss from HF surgery, resulting in a significant demand of blood transfusion. 2 Elderly HF patients with postoperative anemia requiring allogeneic blood transfusion (ABT) also have a significant association with mortality and readmission rates, ambulatory recovery, and poorer functional outcome. 3, 4 Moreover, ABT also increases the risk of postoperative infection, length of hospital stay, and transfusion-related morbidity. 5, 6 In addition to the blood loss from fracture and surgical bleeding, postoperative anemia could be aggravated by inflammatory effect from the surgery, which affects the iron metabolism and then inhibit postoperative erythropoiesis. 7 As a result, the recovery of hemoglobin (Hb) concentration would be slow and requires longer time up to 4 weeks after surgery to return to preinjury level. 8 Among the current methods for correction of the perioperative anemia and reduction of the postoperative blood loss (PBL) and ABT requirement in elderly HF, iron supplement therapy and recombinant human erythropoietin (rHuEPO) injection are ones of the interesting options. Previous studies on the combined subcutaneous (SC) rHuEPO injection and intravenous (IV) iron therapy had revealed the ability to stimulate postoperative erythropoiesis and significantly reduce the ABT. [9] [10] [11] [12] However, the dosage for SC rHuEPO injection in these studies was very high, as 500 -600 IU/kg, due to the poor drug absorption from SC route, which raised the concern of severe drug-related adverse effects, such as severe hypertension and venous thromboembolism (VTE), especially in the high surgical risk elderly HF patients. Moreover, the mean time to surgery in the previous studies was up to 4 days, [11] [12] which was not suitable for the geriatric patients who need urgent surgical intervention. Through our knowledge, the minimum effective rHuEPO dosage to reduce ABT in elderly HF patients is unknown 13 and the efficacy of combined low dose IV rHuEPO (150 -300 IU/kg) and IV iron therapy in these patients had not been investigated before. Therefore, this aim of this study was to evaluate the effect of a single low dose preoperative IV rHuEPO in the elderly HF patients who already received IV iron therapy.
Methods

Participants, Inclusion/Exclusion Criteria, and Randomization
This study was a randomized controlled trial (RCT) in a medical university hospital, between 2013 and 2014. Prior approval was obtained from our institutional review board (No. MURA2013/522). Informed consent was obtained from all patients before the surgery was scheduled, in accordance with the Declaration of Helsinki. The manuscript was prepared according to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guideline. 14 Eligible participants were patients diagnosed as either intertrochanteric fracture or femoral neck fracture undergoing HF surgery during 2013 -2014 period. The inclusion criteria were the patients who were 1) aged over 60 years; 2) having low-energy trauma; 3) having no contraindication for HF surgery, and 4) willing to participate into this study. The exclusion criteria were the patients who were 1) delayed presentation more than 5 days after injury; 2) having too high preoperative Hb as more than 14.5 g/dL; 3) having no contraindication of rHuEPO or iron therapy (myeloproliferative disorder, uncontrolled hypertension, previous acute myocardial infarction or stroke, unstable angina, hemochromatosis, inflammatory arthritis, and allergic to rHuEPO or intravenous iron sucrose); 4) having serum creatinine > 2.0 mg/dL; and 5) having coagulopathy or taking anticoagulant therapy. Patients were randomized by using the computergenerated randomization table with blocks of 4 to receive either an IV injection of 10 000 IU of rHuEPO (Hema-Plus  , Apexcela, Zuellig Pharma Ltd, Bangkok, Thailand) once on admission or placebo (1 mL of normal saline solution). Randomization was concealed with sealed envelopes in sequentially numbered container. On admission, the envelope was opened and the study medication was prepared under sterile conditions by a nurse who was not involved in the care of the patients. All patients were received 3 consequent doses of IV 200-mg iron sucrose (Venofer  , Vifor Pharma, Glattbrugg, Switzerland) on the time of admission, 24 hours and 48 hours from the first dose.
Data Collection
Demographic data such as age, gender, fracture diagnosis, American Society of Anesthesiologist (ASA) physical status, history of taking antiplatelet agents, the time to surgery (the time between admission and operation), preoperative Hb and reticulocyte count (RC) were collected preoperatively by one orthopaedic surgeon (K.L.).
Surgical Procedure and Postoperative Care
HF surgery was performed by the orthopaedic trauma surgeons (P.S., N.K., and N.S.), as soon as the medical condition was stable. The surgical options depended on the fracture type. Femoral neck fractures were treated with bipolar hip replacement using the anterolateral approach with anterior hemimyotomy of the gluteus medius. The decision of femoral stem, either cemented or cementless, depended on the proximal femoral geometry. Intertrochanteric fractures were treated with closed reduction and internal fixation with proximal femoral nail antirotation (PFNA) without cement augmentation.
Perioperative IV fluid maintenance and correction of the third space fluid loss were replaced with balanced crystalloid solutions. Daily Hb level was measured postoperatively until the patients were discharged. Blood transfusion was considered, according to ASA guideline, when Hb level was below than 8 g/dL or the patients had anemic symptoms (dyspnea, tachypnea, and hypoxemia). 15 Postoperative deep vein thrombosis (DVT) prophylaxis protocol, as using mechanical pneumatic pumps early active ankle motion and early ambulation, were applied in all patients. All patients were daily examined postoperatively for clinical signs and symptoms of DVT and pulmonary embolism (PE) until discharge. If DVT or PE were suspected, they were sent for diagnosis by using Doppler ultrasonography or computerized tomogram angiography.
After discharge, all patients were followed at 2 weeks postoperatively for clinical evaluation and laboratory tests (Hb level and RC percentage). Follow-up visit, either outpatient clinic or telephone interview, was scheduled at 3 months, 6 months, and 1 year postoperatively for collecting the postoperative complications.
Outcome Measurement
PBL was defined by using intraoperative blood loss (IBL) and total hemoglobin loss (THL). IBL was quantified by measuring irrigation fluid and weighing surgical sponges used for blood and fluid collection during surgery. THL was calculated from Hb levels at preoperative period, postoperative day 3, and the amount of Postoperative packed red cell (PRC) unit used by using the formula. THL was calculated by the formula based on the assumptions that the blood volume would be the same on admission and on postoperative day 3. To minimize the effect of hemodilution or hemoconcentration the postoperative Hb was measured on the third postoperative day, when the effect of fluid retention may be less prominent than in the earlier postoperative period.
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Hb recovery was defined by the difference of Hb values between preoperative period and postoperative 2 weeks. RC difference at 2 weeks was defined by the difference of RC percentage between postoperative 2 weeks and preoperative period. PRC transfusion was recorded as the number of patients requiring transfusion and the number of PRC unit used. Adverse reactions known to be associated with rHuEPO, such as hypertension, tachycardia, arrhythmia, myalgia, urticarial, thromboembolism, fever, nausea and vomiting, edema, diarrhea or constipation were evaluated during the first 48 hours after operation. Postoperative mortality and morbidity such as cardiac complication (myocardial infarction, cardiac arrhythmia, and congestive heart failure), pulmonary complication (atelectasis, and pneumonia), urinary tract infection, pressure ulcer, and VTE complication (DVT or PE) were collected. Functional outcome, as cumulated ambulatory score (CAS), was used to assess the ambulatory ability at the time of discharge and 2 weeks postoperatively. 17 These data were all collected by one orthopaedic surgeon (K.L.) who was blinded to the treatment allocation.
Sample Size Calculation
The sample size was estimated using Power & Sample Size (PS) version 3.0.0002 (Vanderbilt University, Tennessee, USA) and data from review of 100 elderly HF patients underwent surgical intervention in our hospital before this study which showed the average THL was 2.8 ± 1.2 g/dL. It was assumed that the effect of significant PBL reduction should be 50% with pre-study power of test (β) was set as 0.8 and significant difference (α) as 0.05, the required sample size in each group of the study was 12 patients. Then the sample size was increased by 20% to compensate for expected dropouts, resulting in 16 patients per group.
Statistical Analysis
STATA program version 13.1 (StataCorp. Version 13.1. College Station, TX: StataCorp LP; 2013) was used for statistical analysis. An intention-to-treat analysis was applied to compare the study groups. Normality of the data was tested by Kolmogorov-Smirnov test. Continuous variables were presented as mean and standard deviation (SD), and compared with unpaired t test. Categorical variables were presented as proportion and compared with Fisher exact test or chi-square test. A P value of < .05 was considered significant.
Results
Between 2013 and 2014, 50 elderly HF patients who met the inclusion criteria were enrolled into this study. Eighteen patients were excluded due to refusal to participate (10), serum creatinine more than 2.0 mg% (4) and abnormal coagulation time (4). Therefore, a total of 32 HF patients (3 males and 29 females) were recruited and randomly assigned into 2 groups; 1) EPO group (n = 16), and 2) Control group (n = 16). All patients in both groups were followed our protocol and completed follow-up at one year (Figure 1 ). The average patients' age was 80 years (range, 63 -96 years). There were 21 intertrochanteric fractures (67%) and 11 femoral neck fractures (33%). Nine patients (28%) had received antiplatelet agents before injury. The average time to surgery was 2.5 days (range, 1 -6 days). The average time between rHuEPO administration and operation was 44 hours (range, 1 -115 hours). The average preoperative Hb was 10.9 g/dL (range, 8.8 -14.0 g/dL).
There was no statistically significant difference in preoperative data, in terms of age, gender, fracture type, ASA status, the number of patients receiving antiplatelet therapy, the time from admission to operation, preoperative Hb and preoperative RC percentage between both groups (Table 1) There was no significant difference in the mean THL (2.1 ± 1.0 g/dL vs 2.2 ± 0.8 g/dL, P = .81), the number of patients receiving PRC transfusion (12 patients vs 10 patients, P = .44), and the mean transfused PRC (0.9 ± 0.7 unit vs 0.9 ± 0.9 unit, P = 1.00) between EPO group and control groups. Also, no significant difference in the IBL, length of hospital stay, in-hospital postoperative complications, and CAS score at discharge had been found between both groups (P > .05 all). However, at 2 weeks postoperatively, EPO group demonstrated a nonsignificant better in Hb recovery and a nonsignificant increase in RC difference (0.9 ± 1.4 g/dL and 1.1 ± 0.5%) compared to those in control group (1.8 ± 1.3 g/dL and 0.8 ± 0.7%) (P = .07 and P = .10, respectively) ( Table 2) .
There were 2 patients (1 patient in each group) experienced adverse effects, as anaphylactoid reactions (itching and generalized rash), after IV iron sucrose administration. However, the symptoms were relieved after discontinuation of the drug infusion. None of the patients had the uncontrolled hypertension after the drug administration. None of patients had postoperative symptomatic DVT during the admission period. There was no symptomatic VTE during the one-year follow-up period.
Discussion
Elderly HF and their surgical interventions usually result in a significant amount of blood loss and the need of blood transfusion which can lead to perioperative anemia and its complications, transfusionrelated morbidity or even mortality. Recent studies had demonstrated the efficacy of the combined administration of IV iron and SC rHuEPO for erythropoiesis stimulation and reducing postoperative ABT in elderly HF patients. [9] [10] [11] [12] However, to the best of our knowledge, the information on using IV iron therapy and low dose preoperative IV rHuEPO in elderly HF did not exist in the literature. This study aimed to evaluate the PBL and ABT requirement between the elderly HF patients undergoing the surgical intervention and receiving IV iron sucrose alone and those receiving combine IV iron sucrose and a single shot low dose preoperative IV rHuEPO.
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Regarding to the PBL and ABT requirements, the findings from this study showed that an adjunctive single shot low dose preoperative IV rHuEPO did not significantly reduce THL (P = .81), the need of ABT (P = .44), and the number of PRC transfusion (P = 1.00) in the elderly HF patients who already received IV iron therapy during the admission period. However, at postoperative 2 weeks, EPO group demonstrated a nonsignificantly greater ability of the Hb recovery (P = .07) and a nonsignificant increase of the percentage of RC (P = .10) when compared to the preoperative values. It is implied that the clinical efficacy of rHuEPO administration, either SC or IV route, should be dose-dependent. In addition, although the mean time to surgery in the present study (2.9 days) was faster than the previous studies, 11, 12 an add-on single shot low dose preoperative IV rHuEPO with iron therapy should not be clearly seen in a few days postoperatively but able to be detected as early as 2 weeks postoperatively instead. However, the sample size of this study might be too small to detect the difference of these outcomes at 2 weeks postoperatively. Nonetheless, these evidences could support the theoretical advantage of this adjunctive strategy of IV rHuEPO together with IV iron therapy for erythropoiesis stimulation and correction of anemia in the treatment of elderly HF as same as in the previous studies. [9] [10] [11] [12] The results of the present study also demonstrated that the postoperative complications and length of hospital stay, the drug-related adverse effects (anaphylactoid reactions, uncontrolled hypertension, DVT), and the 2-week postoperative functional outcomes, CAS, were not significantly different between both groups (P > .05 all). These findings also support the safety and efficacy of this erythropoiesis stimulation strategy for the elderly HF treatment.
Our study also had some limitations. Firstly, the sample size in this study might be too small for detecting the other interesting outcomes that related to rHuEPO treatment, such as postoperative Hb recovery, RC difference, and the improvement of the functional outcome as we previously mentioned. However, our study was designed as a prospective RCT, which would help for eliminating the confounding factors and selection bias. Secondly, this study did not compare the results between IV with SC rHuEPO. However, the dosage of SC rHuEPO is the previous studies is very high (40 000 unit) and there were only few studies investigating on its safety. Therefore, due to the concerns of our IRB, we decided to perform the study only with a low dose preoperative IV rHuEPO. Lastly, the laboratory investigations related to anemia, such as ferritin level, did not performed.
Conclusions
This study demonstrated that the addition of a single shot low dose preoperative intravenous rHuEPO in elderly HF patients undergoing surgical intervention and receiving intravenous iron therapy was not significantly associated with the reduction of postoperative blood loss or transfusion requirement. However, this adjunct rHuEPO may hasten the Hb recovery and be beneficial for the patients' outcome.
